HHS working with Emergent on Zika vaccine

HHS's Biomedical Advanced Research and Development Authority (BARDA) will provide Emergent BioSolutions Inc. (NYSE:EBS) at least $17.9 million over the next 30 months to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase I study.

Emergent, which is one of HHS's Centers for Innovation in Advanced Development and Manufacturing, will use vaccine technology similar to that used in vaccines for similar viruses including dengue. ...